<!DOCTYPE html>
<html lang="en">
<head id="Head1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <meta http-equiv="content-type" content="text/html;charset=utf-8" />
    <meta http-equiv="X-UA-Compatible" content="IE=Edge" />
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1.0" />
    <title>Full Text of HB2584</title>
    <link rel="shortcut icon" type="image/x-icon" href="https://cdn.ilga.gov/assets/img/site/favicon.ico" />
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap.min.css" />
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <link href="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.css" rel="stylesheet">
    <script src="https://cdn.ilga.gov/assets/js/fontawesome/fa.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/jquery.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/js.cookie.min.js"></script>
    <script async src="https://cse.google.com/cse.js?cx=a47f92b5e11c1499a"></script> 
    <!-- Bootstrap Datepicker CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/assets/css/bootstrap/bootstrap-4.6.2-dist/css/bootstrap-datepicker.min.css">
    <!-- Bootstrap Datepicker JavaScript -->
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap-datepicker.min.js"></script>
    <!-- aos, bootstrap icons, swiper CSS -->
    <link href="https://cdn.ilga.gov/assets/css/aos/aos.css" rel="stylesheet">
    <link href="https://cdn.ilga.gov/assets/css/swiper/swiper-bundle.min.css" rel="stylesheet">

    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/bootstrap-table.min.js"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/bootstrap-table/1.18.3/extensions/filter-control/bootstrap-table-filter-control.min.js"></script>

    <!-- ILGA main CSS -->
    <link rel="stylesheet" href="https://cdn.ilga.gov/main.css" />
    <link rel="stylesheet" type="text/css" media="print" href="https://cdn.ilga.gov/assets/css/print.css">
    <style></style>
    
</head>
<body>
        <!-- ======= Header ======= -->
        <header id="print-header" class="d-flex align-items-center">
            <div class="container-fluid align-items-center text-uppercase justify-content-start ">
                <div class="logo ">
                    <a href="/"><img src="https://cdn.ilga.gov/assets/img/site/white_capitol.png" alt="ILGA Logo"><span>ILGA.GOV</span></a>
                </div>
                <div class="w-100"></div>
            </div>
        </header>
    <input id="TextSearch" type="hidden" />
    <input id="MobileTextSearch" type="hidden" />
    <input id="message-input" type="hidden" />

    <main id="main-content" role="main">
        <section class="main-page p-2">
	<div class="p-1 pt-4 float-left">
		<div class="row border-bottom pb-3 mb-3">
			<div class="text-start">
				<h2>
					HB2584 - 104th General Assembly
				</h2><br />
			</div>
		</div>
		<div id="content">
			<!-- Full text only shows on large screens -->
			<div class="centered-container d-lg-flex">
				<div class="left-aligned-content">
					<div class="row">
						<div class="col pl-lg-5" translate="no">
							<text class="ml-5 text-left fulltextLineHeight" id="billtextanchor">
								<style>
								
								
								
								table.xsl	{ 	border-collapse: collapse;
												border: 0px solid black;
												font-family: "courier New"; 
												font-size: 10pt;}
								
								td.xsl		{ 	border-collapse: collapse;
												border: 0px solid black;
												padding-top: 3pt;
												padding-bottom: 3pt;
												padding-left: 0pt;
												padding-right: 0pt;
												font-family: "courier New"; 
												font-size: 10pt; }
												
								td.junk		{ 	width: 5%; }
								 
							
					
					
						body.xsl		{ 	text-align:center; }
						
					
						td.lineNum 		{ 	vertical-align: top; 
										  	text-align: right;
										  	font-family: "courier New"; 
										  	font-size: 10pt; }
							
						td.number 		{	width: 5%;
											vertical-align: top; 
										  	text-align: right;
										  	font-family: "Courier New", sans-serif;
										  	font-size: 10pt; }
						
						td.synopsis		{ 	border-collapse: collapse;
											border: 0px solid black;
											padding-top: 0pt;
											padding-bottom: 0pt;
											padding-left: 0pt;
											padding-right: 0pt;
											font-family: "courier New"; 
											font-size: 10pt; }
						
						td.rowsep		{ 	border-bottom: 1px solid black; }
											
						td.colsep		{ 	border-right: 1px solid black; }
											
						td.bothsep		{ 	border-right: 1px solid black;
										  	border-bottom: 1px solid black; }
	
						table.top		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black; }
											
						table.bottom	{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-bottom: 1px solid black; }
											
						table.sides		{ 	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black; }
	
						table.all		{ 	font-family: "Courier New", sans-serif;
										  	font-size: 10pt;
									  	  	border-left: 1px solid black;
									  	  	border-right: 1px solid black;
									  	  	border-bottom: 1px solid black;
									  	  	border-top: 1px solid black; }				
	
						table.topbot	{ 	border-collapse: separate;
									  	  	border: outset 0pt;
										  	font-family: "Courier New", sans-serif;
									  	  	font-size: 10pt;
									  	  	border-top: 1px solid black;
									  	  	border-bottom: 1px solid black; }
					
						.sigline		{ 	text-align: left;
							 		 		vertical-align: bottom;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.siglinetext		{ 	text-align: left;
							 		 		vertical-align: top;
							 				padding-top: 3pt;
							 				padding: 0pt; }
							 				
						.sigtitle		{ 	text-align: left;
							 				vertical-align: top;
							 				padding: 0pt; }
							 				  
						.sigtitlenum		{ 	text-align: right;
							 				vertical-align: top;
							 				padding: 0pt; }
							
						.siglinenum		{ 	text-align: right;
							 				vertical-align: center;
							 				padding-top: 3pt;
							 				padding: 0pt; }
					</style><table class="xsl" width="578"><pre><tr><td class="xsl" colspan="3"><p> </p><br> </td></tr><p><b>Rep. Kelly M. Cassidy</b></p><p><b>Filed: 3/10/2025</b></p><p> </p><p> </p><br> </td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center"></td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><center><code>AMENDMENT TO HOUSE BILL 2584 </code></center><br></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>AMENDMENT NO. ______. Amend House Bill 2584 by replacing </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>everything after the enacting clause with the following:</code><br> </td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Section 5. </code><code>The Illinois Insurance Code is amended by </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>changing Section 356z.60 as follows:</code><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(215 ILCS 5/356z.60)</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 356z.60. </code><code>Coverage for abortifacients, hormonal </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>therapy, and human immunodeficiency virus pre-exposure </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>prophylaxis and post-exposure prophylaxis.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) As used in this Section:</code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Abortifacients" means any medication administered to </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>terminate a pregnancy as prescribed or ordered by a health </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>care professional.</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Health care professional" means a physician licensed to </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>practice medicine in all of its branches, licensed advanced </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>practice registered nurse, or physician assistant.</code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 2 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Hormonal therapy medication" means hormonal treatment </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>administered to treat gender dysphoria.</code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>"Therapeutic equivalent version" means drugs, devices, or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>products that can be expected to have the same clinical effect </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>and safety profile when administered to patients under the </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>conditions specified in the labeling and that satisfy the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>following general criteria:</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) it is approved as safe and effective;</code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) it is a pharmaceutical equivalent in that it:</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) contains identical amounts of the same active </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >        <code>drug ingredient in the same dosage form and route of </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >        <code>administration; and</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) meets compendial or other applicable standards </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" >        <code>of strength, quality, purity, and identity;</code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) it is bioequivalent in that:</code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(A) it does not present a known or potential </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" >        <code>bioequivalence problem and it meets an acceptable in </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" >        <code>vitro standard; or</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>    </code><code>(B) if it does present such a known or potential </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" >        <code>problem, it is shown to meet an appropriate </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >        <code>bioequivalence standard;</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(4) it is adequately labeled; and</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(5) it is manufactured in compliance with Current Good </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>Manufacturing Practice regulations adopted by the United </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>States Food and Drug Administration.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) An individual or group policy of accident and health </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 3 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>insurance amended, delivered, issued, or renewed in this State </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>on or after January 1, 2024 shall provide coverage for all </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>abortifacients, hormonal therapy medication, human </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>immunodeficiency virus pre-exposure prophylaxis, and </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>post-exposure prophylaxis drugs approved by the United States </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>Food and Drug Administration, and follow-up services related </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>to that coverage, including, but not limited to, management of </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>side effects, medication self-management or adherence </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>counseling, risk reduction strategies, and mental health </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>counseling. This coverage shall include drugs approved by the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>United States Food and Drug Administration that are prescribed </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>or ordered for off-label use for the purposes described in </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>this Section. </code><u><code>On or after the effective date of this </code></u></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><u><code>amendatory Act of the 104th General Assembly, this coverage </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>shall include pre-PrEP HIV screening, sexually transmitted </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><u><code>infection screening, kidney function analysis, routine </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><u><code>laboratory testing, and routine provider visits.</code></u><code> </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) The coverage required under subsection (b) is subject </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>to the following conditions:</code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(1) If the United States Food and Drug Administration </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" >    <code>has approved one or more therapeutic equivalent versions </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" >    <code>of an abortifacient drug, a policy is not required to </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" >    <code>include all such therapeutic equivalent versions in its </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" >    <code>formulary so long as at least one is included and covered </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" >    <code>without cost sharing and in accordance with this Section.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(2) If an individual's attending provider recommends a </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 4 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" >    <code>particular drug approved by the United States Food and </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" >    <code>Drug Administration based on a determination of medical </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" >    <code>necessity with respect to that individual, the plan or </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" >    <code>issuer must defer to the determination of the attending </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" >    <code>provider and must cover that service or item without cost </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" >    <code>sharing.</code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>    </code><code>    </code><code>(3) If a drug is not covered, plans and issuers must </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" >    <code>have an easily accessible, transparent, and sufficiently </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" >    <code>expedient process that is not unduly burdensome on the </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" >    <code>individual or a provider or other individual acting as a </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" >    <code>patient's authorized representative to ensure coverage </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" >    <code>without cost sharing.</code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>The conditions listed under this subsection (c) also apply </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>to drugs prescribed for off-label use as abortifacients. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) Except as otherwise provided in this Section, a policy </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>subject to this Section shall not impose a deductible, </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>coinsurance, copayment, or any other cost-sharing requirement </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>on the coverage provided. The provisions of this subsection do </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>not apply to coverage of procedures to the extent such </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>coverage would disqualify a high-deductible health plan from </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>eligibility for a health savings account pursuant to the </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>federal Internal Revenue Code, 26 U.S.C. 223.</code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) Except as otherwise authorized under this Section, a </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>policy shall not impose any restrictions or delays on the </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>coverage required under this Section.</code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) The coverage requirements in this Section for </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 5 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>abortifacients do not, pursuant to 42 U.S.C. 18054(a)(6), </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>apply to a multistate plan that does not provide coverage for </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>abortion.</code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) If the Department concludes that enforcement of any </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>coverage requirement of this Section for abortifacients may </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>adversely affect the allocation of federal funds to this </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>State, the Department may grant an exemption to that </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>requirement, but only to the minimum extent necessary to </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>ensure the continued receipt of federal funds.</code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 102-1117, eff. 1-13-23; 103-462, eff. 8-4-23.)</code><br> </td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 10. </code><code>The Prior Authorization Reform Act is amended </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>by adding Section 52 as follows:</code><br> </td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(215 ILCS 200/52 new)</code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 52. </code></u><u><code>Prior authorization for certain prescription </code></u></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><u><code>drugs; prohibited. </code></u><u><code>A health insurance issuer may not require </code></u></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><u><code>prior authorization for the following prescription drug types </code></u></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><u><code>and their therapeutic equivalents approved by the United </code></u></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><u><code>States Food and Drug Administration: human immunodeficiency </code></u></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><u><code>virus pre-exposure prophylaxis and post-exposure prophylaxis </code></u></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><u><code>medication or human immunodeficiency virus treatment </code></u></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><u><code>medication.</code></u><br> </td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 15. </code><code>The Illinois Public Aid Code is amended by </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>changing Section 5-5.12 and by adding Section 5-54 as follows:</code><br> </td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 6 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(305 ILCS 5/5-5.12)</code><code>  </code><code>(from Ch. 23, par. 5-5.12)</code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Sec. 5-5.12. </code><code>Pharmacy payments. </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(a) Every request submitted by a pharmacy for </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>reimbursement under this Article for prescription drugs </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>provided to a recipient of aid under this Article shall </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>include the name of the prescriber or an acceptable </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>identification number as established by the Department.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(b) Pharmacies providing prescription drugs under this </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>Article shall be reimbursed at a rate which shall include a </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>professional dispensing fee as determined by the Illinois </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Department, plus the current acquisition cost of the </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>prescription drug dispensed. The Illinois Department shall </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>update its information on the acquisition costs of all </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>prescription drugs no less frequently than every 30 days. </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>However, the Illinois Department may set the rate of </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>reimbursement for the acquisition cost, by rule, at a </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>percentage of the current average wholesale acquisition cost.</code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(c) (Blank).</code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(d) The Department shall review utilization of narcotic </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>medications in the medical assistance program and impose </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>utilization controls that protect against abuse. </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(e) When making determinations as to which drugs shall be </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>on a prior approval list, the Department shall include as part </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>of the analysis for this determination, the degree to which a </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>drug may affect individuals in different ways based on factors </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 7 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>including the gender of the person taking the medication. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(f) The Department shall cooperate with the Department of </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>Public Health and the Department of Human Services Division of </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>Mental Health in identifying psychotropic medications that, </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>when given in a particular form, manner, duration, or </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>frequency (including "as needed") in a dosage, or in </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>conjunction with other psychotropic medications to a nursing </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>home resident or to a resident of a facility licensed under the </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>ID/DD Community Care Act or the MC/DD Act, may constitute a </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>chemical restraint or an "unnecessary drug" as defined by the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>Nursing Home Care Act or Titles XVIII and XIX of the Social </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>Security Act and the implementing rules and regulations. The </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Department shall require prior approval for any such </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>medication prescribed for a nursing home resident or to a </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>resident of a facility licensed under the ID/DD Community Care </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Act or the MC/DD Act, that appears to be a chemical restraint </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>or an unnecessary drug. The Department shall consult with the </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>Department of Human Services Division of Mental Health in </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>developing a protocol and criteria for deciding whether to </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>grant such prior approval. </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g) The Department may by rule provide for reimbursement </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>of the dispensing of a 90-day supply of a generic or brand </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>name, non-narcotic maintenance medication in circumstances </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>where it is cost effective. </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(g-5) On and after July 1, 2012, the Department may </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>require the dispensing of drugs to nursing home residents be </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 8 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>in a 7-day supply or other amount less than a 31-day supply. </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>The Department shall pay only one dispensing fee per 31-day </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>supply. </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h) Effective July 1, 2011, the Department shall </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>discontinue coverage of select over-the-counter drugs, </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>including analgesics and cough and cold and allergy </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>medications. </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(h-5) </code><u><code>The</code></u><code> </code><strike><code>On and after July 1, 2012, the</code></strike><code> Department shall </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>impose utilization controls, including, but not limited to, </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>prior approval on specialty drugs, oncolytic drugs, </code><strike><code>drugs for </code></strike></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><strike><code>the treatment of HIV or AIDS,</code></strike><code> immunosuppressant drugs, and </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>biological products in order to maximize savings on these </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>drugs. The Department may adjust payment methodologies for </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>non-pharmacy billed drugs in order to incentivize the </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>selection of lower-cost drugs. </code><strike><code>For drugs for the treatment of </code></strike></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><strike><code>AIDS, the Department shall take into consideration the </code></strike></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><strike><code>potential for non-adherence by certain populations, and shall </code></strike></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><strike><code>develop protocols with organizations or providers primarily </code></strike></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><strike><code>serving those with HIV/AIDS, as long as such measures intend </code></strike></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><strike><code>to maintain cost neutrality with other utilization management </code></strike></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><strike><code>controls such as prior approval.</code></strike><code> For hemophilia, the </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>Department shall develop a program of utilization review and </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>control which may include, in the discretion of the </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>Department, prior approvals. The Department may impose special </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>standards on providers that dispense blood factors which shall </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>include, in the discretion of the Department, staff training </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 9 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>and education; patient outreach and education; case </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>management; in-home patient assessments; assay management; </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>maintenance of stock; emergency dispensing timeframes; data </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>collection and reporting; dispensing of supplies related to </code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>blood factor infusions; cold chain management and packaging </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>practices; care coordination; product recalls; and emergency </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>clinical consultation. The Department may require patients to </code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>receive a comprehensive examination annually at an appropriate </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>provider in order to be eligible to continue to receive blood </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>factor. </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(i) On and after July 1, 2012, the Department shall reduce </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>any rate of reimbursement for services or other payments or </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>alter any methodologies authorized by this Code to reduce any </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>rate of reimbursement for services or other payments in </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>accordance with Section 5-5e. </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(j) On and after July 1, 2012, the Department shall impose </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>limitations on prescription drugs such that the Department </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>shall not provide reimbursement for more than 4 prescriptions, </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>including 3 brand name prescriptions, for distinct drugs in a </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>30-day period, unless prior approval is received for all </code></td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>prescriptions in excess of the 4-prescription limit. Drugs in </code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>the following therapeutic classes shall not be subject to </code></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><code>prior approval as a result of the 4-prescription limit: </code></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><code>immunosuppressant drugs, oncolytic drugs, anti-retroviral </code></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><code>drugs, and, on or after July 1, 2014, antipsychotic drugs. On </code></td></tr><tr><td class="number">26</td><td class="junk"></td><td class="xsl" ><code>or after July 1, 2014, the Department may exempt children with </code></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 10 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><code>complex medical needs enrolled in a care coordination entity </code></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><code>contracted with the Department to solely coordinate care for </code></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><code>such children, if the Department determines that the entity </code></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><code>has a comprehensive drug reconciliation program.</code></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(k) No medication therapy management program implemented </code></td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>by the Department shall be contrary to the provisions of the </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>Pharmacy Practice Act.</code></td></tr><tr><td class="number">8</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(l) Any provider enrolled with the Department that bills </code></td></tr><tr><td class="number">9</td><td class="junk"></td><td class="xsl" ><code>the Department for outpatient drugs and is eligible to enroll </code></td></tr><tr><td class="number">10</td><td class="junk"></td><td class="xsl" ><code>in the federal Drug Pricing Program under Section 340B of the </code></td></tr><tr><td class="number">11</td><td class="junk"></td><td class="xsl" ><code>federal Public Health Service Act shall enroll in that </code></td></tr><tr><td class="number">12</td><td class="junk"></td><td class="xsl" ><code>program. No entity participating in the federal Drug Pricing </code></td></tr><tr><td class="number">13</td><td class="junk"></td><td class="xsl" ><code>Program under Section 340B of the federal Public Health </code></td></tr><tr><td class="number">14</td><td class="junk"></td><td class="xsl" ><code>Service Act may exclude fee-for-service Medicaid from their </code></td></tr><tr><td class="number">15</td><td class="junk"></td><td class="xsl" ><code>participation in that program, however, entities defined in </code></td></tr><tr><td class="number">16</td><td class="junk"></td><td class="xsl" ><code>Section 1905(l)(2)(B) of the Social Security Act are excluded </code></td></tr><tr><td class="number">17</td><td class="junk"></td><td class="xsl" ><code>from this requirement. This subsection does not apply to </code></td></tr><tr><td class="number">18</td><td class="junk"></td><td class="xsl" ><code>outpatient drugs billed to Medicaid managed care </code></td></tr><tr><td class="number">19</td><td class="junk"></td><td class="xsl" ><code>organizations. </code></td></tr><tr><td class="number">20</td><td class="junk"></td><td class="xsl" ><code>(Source: P.A. 102-558, eff. 8-20-21; 102-778, eff. 7-1-22.)</code><br> </td></tr><tr><td class="number">21</td><td class="junk"></td><td class="xsl" ><code>    </code><code>(305 ILCS 5/5-54 new)</code></td></tr><tr><td class="number">22</td><td class="junk"></td><td class="xsl" ><code>    </code><u><code>Sec. 5-54. </code></u><u><code>Prior authorization for certain prescription </code></u></td></tr><tr><td class="number">23</td><td class="junk"></td><td class="xsl" ><u><code>drugs; prohibited. </code></u><u><code>The fee-for-service medical assistance </code></u></td></tr><tr><td class="number">24</td><td class="junk"></td><td class="xsl" ><u><code>program and a Medicaid managed care organization may not </code></u></td></tr><tr><td class="number">25</td><td class="junk"></td><td class="xsl" ><u><code>require prior authorization for the following prescription </code></u></td></tr></table><table class="xsl" width="578"><tr><td class="lineNum" colspan="3"><p> </p><p> </p></td></tr><tr><td class="xsl" colspan="3"><table class="xsl" width="100%"><colgroup width="5%"></colgroup><colgroup width="5%"></colgroup><colgroup width="30%"></colgroup><colgroup width="20%"></colgroup><colgroup width="40%"></colgroup><tr><td class="number"></td><td class="junk"></td><td class="xsl" align="left">10400HB2584ham001</td><td class="xsl" align="center">- 11 -</td><td class="xsl" align="right">LRB104 08321 BAB 23420 a</td></tr></table></td></tr><tr><td class="xsl"><br></td></tr><tr><td class="number">1</td><td class="junk"></td><td class="xsl" ><u><code>drug types and their therapeutic equivalents approved by the </code></u></td></tr><tr><td class="number">2</td><td class="junk"></td><td class="xsl" ><u><code>United States Food and Drug Administration: human </code></u></td></tr><tr><td class="number">3</td><td class="junk"></td><td class="xsl" ><u><code>immunodeficiency virus pre-exposure prophylaxis and </code></u></td></tr><tr><td class="number">4</td><td class="junk"></td><td class="xsl" ><u><code>post-exposure prophylaxis medication or human immunodeficiency </code></u></td></tr><tr><td class="number">5</td><td class="junk"></td><td class="xsl" ><u><code>virus treatment medication.</code></u><br> </td></tr><tr><td class="number">6</td><td class="junk"></td><td class="xsl" ><code>    </code><code>Section 99. </code><code>Effective date. </code><code>This Act takes effect January </code></td></tr><tr><td class="number">7</td><td class="junk"></td><td class="xsl" ><code>1, 2027.".</code></pre></table>
							</text>
						</div>
					</div>
				</div>
			</div>
		</div>
    </div>
</section>
    </main>
    <!-- Vendor JS Files -->
    <script src="https://cdn.ilga.gov/assets/js/aos/aos.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/jquery/popper.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/bootstrap/bootstrap.bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/glightbox/glightbox.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/swiper/swiper-bundle.min.js"></script>
    <script src="https://cdn.ilga.gov/assets/js/main.js"></script>

    

</body>
</html>
